Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Enliven Therapeutics Inc shares valued at $230,375 were purchased by Kintz Samuel on Sep 17 ’25. At $18.43 per share, Kintz Samuel acquired 12,500 shares.
Also, Patel Anish sold 6,667 shares, netting a total of over 134,957 in proceeds. Following the sale of shares at $20.24 each, the insider now holds 283,308 shares.
Before that, Patel Anish had added 20,001 shares to its account. In a trade valued at $403,020, the Officer bought Enliven Therapeutics Inc shares for $20.15 each.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] rose 4.76% to $19.92. The stock’s lowest price that day was $18.78, but it reached a high of $19.99 in the same session. During the last five days, there has been a surge of approximately 0.03%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -10.97%.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.18 million shares to 4.89 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 5.08 million shares. A decline of -3.78% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.82 of the overall float, the days-to-cover ratio (short ratio) decline to 11.82.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 45.5 in the next 12 months, up nearly 139.22% from the previous closing price of $19.02. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2025, with the lowest price target being 39. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2025. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
